PDF(Pubmed)
Abstract：
UNASSIGNED: Vaginitis is a common infection in women, with approximately 75% of women experiencing at least one episode during their lifetime. Although antimicrobial agents are widely used to treat vaginitis, recurrent vaginitis occurs in some patients. Resistance to these agents is the major cause of recurrent vaginitis. Therefore, there is an urgent need to develop novel drugs.
UNASSIGNED: We investigated the efficacy of a new biological bacteriostatic agent (BBA), composed of lysozyme, phytoalexin, chitosan oligosaccharide, sinensetin, 18β/20α-glycyrrhizin, and betaine, against vaginitis using in vitro and in vivo studies. First, we evaluated the antibacterial effects of BBA against 13 microbial strains commonly present in aerobic vaginitis, bacterial vaginosis, vulvovaginal candidiasis, and healthy vaginas. Second, we assessed the safety of various doses of BBA administered orally for 4 weeks in female mice. Third, we examined the in vivo anti-proliferative and anti-inflammatory effects of BBA in Candida albicans-, Candida glabrata-, and Gardnerella-induced vaginitis models. Finally, we evaluated the anti-vaginitis effect of a BBA gel prepared with 0.5% (w/v) ammonium acryloyldimethyltaurate/Vp copolymer.
UNASSIGNED: BBA effectively suppressed the growth of the main causative pathogens of vaginitis in vitro. BBA, either undiluted or diluted two-fold, inhibited all microorganisms cultured for 8 h. No obvious organ damage was detected when BBA was administered to mice. Both BBA alone and 70% BBA in a gel formulation effectively inhibited the proliferation of C. albicans, C. glabrata, and Gardnerella in vaginal lavage samples and alleviated tissue inflammation in mice with vaginitis. The 70% BBA gel performed better than BBA alone at treating vaginitis in mice infected with Gardnerella vaginalis.
UNASSIGNED: BBA alone and a 70% BBA gel inhibited the growth of pathogens and effectively alleviated inflammation caused by C. albicans, C. glabrata, and G. vaginalis.
UNASSIGNED: We investigated the efficacy of a new biological bacteriostatic agent (BBA), composed of lysozyme, phytoalexin, chitosan oligosaccharide, sinensetin, 18β/20α-glycyrrhizin, and betaine, against vaginitis using in vitro and in vivo studies. First, we evaluated the antibacterial effects of BBA against 13 microbial strains commonly present in aerobic vaginitis, bacterial vaginosis, vulvovaginal candidiasis, and healthy vaginas. Second, we assessed the safety of various doses of BBA administered orally for 4 weeks in female mice. Third, we examined the in vivo anti-proliferative and anti-inflammatory effects of BBA in Candida albicans-, Candida glabrata-, and Gardnerella-induced vaginitis models. Finally, we evaluated the anti-vaginitis effect of a BBA gel prepared with 0.5% (w/v) ammonium acryloyldimethyltaurate/Vp copolymer.
UNASSIGNED: BBA effectively suppressed the growth of the main causative pathogens of vaginitis in vitro. BBA, either undiluted or diluted two-fold, inhibited all microorganisms cultured for 8 h. No obvious organ damage was detected when BBA was administered to mice. Both BBA alone and 70% BBA in a gel formulation effectively inhibited the proliferation of C. albicans, C. glabrata, and Gardnerella in vaginal lavage samples and alleviated tissue inflammation in mice with vaginitis. The 70% BBA gel performed better than BBA alone at treating vaginitis in mice infected with Gardnerella vaginalis.
UNASSIGNED: BBA alone and a 70% BBA gel inhibited the growth of pathogens and effectively alleviated inflammation caused by C. albicans, C. glabrata, and G. vaginalis.
摘要：
■阴道炎是女性常见的感染，大约75%的女性一生中至少经历过一次发作。虽然抗菌剂被广泛用于治疗阴道炎，复发性阴道炎发生在一些患者中。对这些药物的抗性是复发性阴道炎的主要原因。因此,迫切需要开发新药物。
■我们研究了一种新型生物抑菌剂（BBA）的功效，由溶菌酶组成，植物抗毒素,壳寡糖，sinensetin,18β/20α-甘草酸，和甜菜碱,使用体外和体内研究对抗阴道炎。首先,我们评估了BBA对需氧性阴道炎中常见的13种微生物菌株的抗菌作用，细菌性阴道病,外阴阴道念珠菌病,和健康的阴道。第二,我们评估了雌性小鼠口服不同剂量BBA4周的安全性。第三，我们检查了BBA在白色念珠菌中的体内抗增殖和抗炎作用-，光亮念珠菌-,和加德纳菌诱导的阴道炎模型。最后,我们评估了用0.5％（w/v）丙烯酰二甲基牛磺酸铵/Vp共聚物制备的BBA凝胶的抗阴道炎作用。
■BBA在体外有效抑制了阴道炎的主要病原体的生长。BBA,未稀释或稀释两倍，抑制所有培养8小时的微生物。对小鼠施用BBA时未检测到明显的器官损伤。单独的BBA和凝胶制剂中的70％BBA均有效抑制白色念珠菌的增殖，C.光滑，阴道灌洗样品中的加德纳菌和减轻阴道炎小鼠的组织炎症。70％BBA凝胶在治疗感染阴道加德纳菌的小鼠阴道炎方面比单独的BBA表现更好。
■单独的BBA和70％的BBA凝胶抑制病原体的生长，并有效减轻白色念珠菌引起的炎症，C.光滑，和阴道G.
■我们研究了一种新型生物抑菌剂（BBA）的功效，由溶菌酶组成，植物抗毒素,壳寡糖，sinensetin,18β/20α-甘草酸，和甜菜碱,使用体外和体内研究对抗阴道炎。首先,我们评估了BBA对需氧性阴道炎中常见的13种微生物菌株的抗菌作用，细菌性阴道病,外阴阴道念珠菌病,和健康的阴道。第二,我们评估了雌性小鼠口服不同剂量BBA4周的安全性。第三，我们检查了BBA在白色念珠菌中的体内抗增殖和抗炎作用-，光亮念珠菌-,和加德纳菌诱导的阴道炎模型。最后,我们评估了用0.5％（w/v）丙烯酰二甲基牛磺酸铵/Vp共聚物制备的BBA凝胶的抗阴道炎作用。
■BBA在体外有效抑制了阴道炎的主要病原体的生长。BBA,未稀释或稀释两倍，抑制所有培养8小时的微生物。对小鼠施用BBA时未检测到明显的器官损伤。单独的BBA和凝胶制剂中的70％BBA均有效抑制白色念珠菌的增殖，C.光滑，阴道灌洗样品中的加德纳菌和减轻阴道炎小鼠的组织炎症。70％BBA凝胶在治疗感染阴道加德纳菌的小鼠阴道炎方面比单独的BBA表现更好。
■单独的BBA和70％的BBA凝胶抑制病原体的生长，并有效减轻白色念珠菌引起的炎症，C.光滑，和阴道G.
